vivoVerse develops microfluidics and AI/ML technologies to assess the toxicological safety profiles of chemicals using C. elegans as a New Approach Methodology. This approach significantly reduces reliance on animal testing, providing a faster and more ethical alternative for chemical safety evaluation.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional chemical safety assessments rely heavily on animal testing, which is expensive, time-consuming, and raises ethical concerns. These methods often lack the throughput and sensitivity needed to efficiently evaluate the toxicological profiles of a growing number of chemicals.
Solution
vivoVerse offers a microfluidics-based platform that leverages _C. elegans_ and AI/ML to provide rapid and ethical toxicological safety assessments of chemicals. Their approach significantly reduces the reliance on animal testing by using nematode worms in high-throughput screening assays. The platform automates data acquisition and processing, providing faster results and more comprehensive safety profiles. vivoVerse's technology enables researchers and companies to efficiently evaluate chemical toxicity, identify potential risks, and make informed decisions about product development and regulatory compliance.
Target Audience
vivoVerse targets researchers, product development teams, and regulatory agencies in the chemical, pharmaceutical, and cosmetics industries seeking faster, more ethical, and cost-effective methods for chemical safety evaluation.
Features
- Microfluidic chips for high-throughput screening of chemicals using _C. elegans_
- Automated imaging and data acquisition systems
- AI/ML-powered data analysis for toxicity prediction
- Customizable assay development for specific toxicological endpoints
- GLP and GMP compliance support
- _vivo_ Cube rental plans available